$GGBXF Yale Teams Up With Weed Company to Study Effects of Cannabis on Stress

November 13, 2019

The Yale School of Medicine and CT Pharmaceuticals Solutions Inc. have teamed up to conduct a study on the impact of medical marijuana on stress and mental health.

On Friday, Yale and CT Pharmaceuticals announced that they would be conducting a phase-one study on the effects of a variety of cannabis strains with medicinal qualities for alleviating pain and stress. They will also examine other conditions such as PTSD (post-traumatic stress disorder), and opioid replacement.

This is a revolutionary clinical study which is the first of its kind to be approved by the state’s Department of Consumer Protection (DCP) medical marijuana research program to study stress and mental health, said Yale.

The study on stress and mental health will advance CT Pharma’s current research which involves human subjects. CT Pharma’s current research was started in 2016 by Yale’s Dr. Rajita Sinha.

In 2017, the Food and Drug Administration (FDA) gave Sinha in collaboration with the CT Pharma, a go-ahead for an Investigational New Drug application to examine how marijuana products affect subjective and physical responses to stress and pain.

In a news release, Sinha said that there is an increase in the consumption of medical marijuana in America, and it is crucial to understand how it helps in relieving a patient’s symptoms. She further said that the study should come up with new findings on pain and stress management in patients using medical marijuana. It should also contribute to the development of new CBD-based treatments.

The first phase of the study will examine males and females between the ages of 21-45. They must be recreational weed consumers who do not qualify for MMJ cards. The second phase will include men and women suffering from chronic pain between the ages of 21-60. Each of the study participants will be provided with placebo and cannabidiol (CBD). CBD is the non-psychoactive compound of marijuana, famous for its healing and wellness benefits.

The study will also assess marijuana’s side effects, such as increased heart rate, systolic, and diastolic blood pressure as well as other clinical symptoms.

The study on stress and mental health comes days after the Connecticut lawmakers added new conditions such as interstitial cystitis, intractable neuropathic pain, medial arcuate ligament syndrome, and Tourette syndrome to the medical marijuana program. The Connecticut MMJ program now has 36 qualifying conditions for adults and 10 for patients under 18 years.

According to CT Pharma, there are 37,927 patients in the MMJ program, 1,196 certified physicians, 15 licensed dispensaries, and four producers in Connecticut. The largest concentration of registered patients is in Hartford, Fairfield, and New Haven.

CT Pharma has 40 employees, and it is planning to expand by moving into a larger facility, which is 173,000 square-foot located in Rocky Hill. The facility was previously occupied by a pharmaceutical company known as McKesson Corp.

This kind of independent research is what marijuana industry players like Youngevity International Inc. (NASDAQ: YGYI) and Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) have always wanted to see so that the public can be reassured that when the industry says marijuana is beneficial, it is true.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

$YGYI CLR Roasters Granted Exclusive Rights for Hemp Grow, Oil Extraction in Nicaragua

$TGODF Psilocybin Emerging as Powerful Way to Treat Depression, Addiction

November 12, 2019

Palm Beach, FL – November 12, 2019 — Johns Hopkins Medicine and New York University aren’t the only institutions uncovering the benefits of psilocybin mushrooms.  According to a study featured in a 2016 issue of Science Direct, as highlighted by GOOD Magazine, psilocybin mushrooms are effective at treating treatment-resistant depression.  Findings also highlighted the drug as an effective way to treat tobacco and alcohol addiction, as well.  “People who used psychedelics have lower rates of psychological distress and suicidality than those who used no psychedelics.”  As excitement builds, it’s opening a range of opportunity for companies that have already established launching cannabis products including The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), Canopy Growth Corporation (TSX:WEED)(NYSE:CGC), The Green Organic Dutchman (TSX:TGOD) (OTCQX:TGODF), Aphria Inc. (NYSE:APHA)(TSX:APHA), and iAnthus Capital Holdings Inc. (CSE:IAN) (OTCQX:ITHUF).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced that on November 8, 2019 it entered into a definitive agreement with Eurolife Brands (CSE: EURO)(FSE:3CMA) for the exclusive distribution of Yield Growth’s line of mushroom infused coffee mixes being developed through subsidiary Flourish Mushroom Labs Inc.   The distribution agreement grants Eurolife Brands exclusive distribution rights in Germany, the United Kingdom and Switzerland for the mushroom coffee line being developed by Yield Growth subsidiary Flourish Mushroom Labs. The initial exclusivity period is one year with options to extend the term provided certain minimum sales are met.  The agreement also grants Eurolife Brands non-exclusive distribution in other territories for two years, with a provision to exclude one or more territories on two-month notice from Flourish Mushroom Labs.  The parties plan to integrate the mushroom coffee mix products into Eurolife Brands’ e-commerce platform in Q2 2020, after testing and registrations are complete.   The initial line of mushroom coffee mixes will be infused with various wild mushrooms such as Lion’s Mane, Turkey Tail, Reishi, Shitake, Chagas and Cordyceps.  “We are excited to partner with Yield Growth, who has demonstrated expertise in the international launch of products with potent ingredients,” says Shawn Moniz, CEO of Eurolife.   “Our research indicates a huge opportunity to sell the Flourish Mushroom Labs mushroom coffee line to European consumers who are educated and health conscious and demand high quality products that are on the cutting edge of their respective industry segments.”

Other cannabis-related developments from around the markets include:

Canopy Growth Corporation (TSX:WEED)(NYSE:CGC) announced that they have entered into agreements to launch the More Life Growth Company, a fully licensed producer of cannabis based in Drake’s hometown of Toronto, Canada.  “When we first began talks with Drake we were extremely inspired by and aligned with his vision to bring best-in-class cannabis products to the world,” said Mark Zekulin, CEO, Canopy Growth Corporation. “Drake’s perspective as a culture leader and entrepreneur combined with Canopy Growth’s breadth of cannabis knowledge will allow our new company to bring an unmatched cannabis experience to global markets.” Drake’s eclectic career includes experience across a wide variety of industries including music, television, film, fashion, sports, brand development, content curation and social and digital media strategy. Having launched numerous successful brands over the past decade, he is uniquely positioned to bring his innovative eye to the recreational cannabis industry. The opportunity to partner with a world-class company like Canopy Growth on a global scale is really exciting,” shared More Life Growth Company founder, Drake. “The idea of being able to build something special in an industry that is ever growing has been inspiring. More Life and More Blessing.”

The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF) announced that the Company expects to release its third quarter 2019 earnings on Thursday, November 14, 2019 after market close. The Company will hold a conference call conducted by Brian Athaide, Chief Executive Officer, and Sean Bovingdon, Chief Financial Officer, on November 15, 2019 at 9:00 am Eastern to discuss the results and future outlook.

Aphria Inc. (NYSE:APHA)(TSX:APHA) announced it has received a cultivation licence from Health Canada for Aphria Diamond, the Company’s second Leamington, Ontario cannabis greenhouse facility, bringing an additional 1,300,000 square feet of production space with an annual growing capacity of 140,000kg. Combined with the Company’s Aphria One facility and its subsidiary Broken Coast Cannabis, the Company now has more than 2,400,000 square feet of cultivation space capable of reaching a total annualized production capacity of 255,000kg. “We are extremely pleased to receive the licence for our long-awaited Aphria Diamond facility, which more than doubles our Canadian production capacity,” said Irwin D. Simon. “Reaching industry-leading production levels coinciding with the expansion into new categories and new opportunities for cannabis in Canada and around the world is a transformative moment for Aphria Inc.”

iAnthus Capital Holdings Inc. (CSE:IAN)(OTCQX:ITHUF) announced that it will release its third quarter 2019 financial and operating results on Wednesday, November 20, 2019 after the market closes. The Company will host a conference call for financial analysts and investors at 8:30am ET on Thursday, November 21, 2019 to discuss the Company’s third quarter results. The call will be archived and available for replay on iAnthus’ website.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM was compensated thirty five hundred dollars for news coverage of current press releases issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

$SRAX CEO to Host Q3 2019 Financial Results Conference Call

• SRAX, a digital marketing and consumer data management technology company, has multiple recurring revenue streams through various platforms
• SRAX’s CEO Christopher Miglino to be joined by key members of SRAX leadership
• Operational and financial summary call to be webcast live, accessible at company’s website

Digital marketing and consumer data management technology company SRAX Inc.’s (NASDAQ: SRAX) Founder and CEO Christopher Miglino will host the company’s conference call on November 13 at 1:30 p.m. (PST). The call will detail the company’s Q3 2019 operational and financial summary. Joining Miglino on the call will be COO Kristoffer Nelson; CFO Mike Malone; Vice President of SRAX Shopper George Stella; and Vice President of Research Sales Rick McCrady (http://nnw.fm/7yVqs).

SRAX is a digital marketing and consumer data management technology company. Through development of its BIGtoken platform, SRAX offers a secure and transparent environment for consumers to own and earn from their data (http://nnw.fm/s4L2R). Developed by SRAX, BIGtoken can be downloaded from both the App Store and Google Play. This platform boasts over…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

$GGBXF to Hold First Quarter Fiscal 2020 Earnings Conference Call Nov 26

COLUMBUS, OH, Nov. 12, 2019 – Green Growth Brands Inc. (GGB or the Company) (CSE: GGB) (OTCQB: GGBXF) today announced it will report results for the first quarter fiscal 2020 ending September 28, 2019, after market close on Monday, November 25, 2019.

In conjunction with the release of its financial results, GGB will host a conference call with Company management at 8:30 AM ET on Tuesday, November 26, 2019.

Conference Call Information

Conference ID: 54236169

Local Toronto Dial-in Number: (+1) 416 764 8609

Local Vancouver Dial-in Number: (+1) 778 383 7417

North American Toll-Free Number:(+1) 888 390 0605

The call and replay archive will be accessible on Green Growth Brands’ Investor Relations website.

About Green Growth Brands Inc.
Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. GGB is expanding its cannabis operations throughout the U.S., via dispensaries in Nevada, Massachusetts and Florida and the largest network of CBD shops in malls across the country and ShopSeventhSense.com. Learn more about the vision at  GreenGrowthBrands.com.

Cautionary Statements:

Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions.  Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018, which is available on the Company’s issuer profile on SEDAR.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including, but not limited to, the Company’s ability to execute on its growth strategy, the Company’s vision to become a multi-state operator with retail stores exceeding certain financial thresholds is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

$CNPOF $RIV.V Can CBD Help Cure Hangovers?

November 12, 2019

Nothing brings you down from a fun night faster than a hangover. For years, people have tried all kinds of home remedies to help them transition from a night of partying to breakfast without the terrible hangover that comes in between, but sadly, none have worked. Well, you’ll be happy to know that apparently, a little known product called cannabidiol (CBD) just might do the trick and finally offer you a reprieve from hangovers.

Now, alcohol has a range of effects on your body, most of which result in the dreaded hangover. Large amounts of alcohol lead to dehydration, irritation and increased acid production in the gastrointestinal system, electrolyte imbalances, low blood sugar, vasodilation, and low quality sleep.

All of these issues result in the symptoms we collectively refer to as a hangover. These usually include headaches, dizziness, nausea, vomiting, diarrhea, irritability, and fatigue. All of these symptoms are incredibly uncomfortable, and they will put you down for a while, whether you like it or not. But the question is, can CBD somehow alleviate them and purge you of your hangover?

Most hangovers are characterized by nausea, dizziness, and vomiting, and CBD is quite effective at managing these symptoms. Unlike conventional nausea treatments that result in side effects such as black spots on the tongue and a constant ringing noise in the ears, CBD is completely side effect-free.

The cannabis extract works by interacting directly with the endocannabinoid system, a peripheral nervous system that regulates feelings of nausea and regurgitation. It stimulates a neurotransmitter (5-Hydroxytryptamine), which then counteracts the neurotransmitters responsible for inducing vomiting. It also stimulates CB1 (cannabinoid) receptors in the gastrointestinal tract, not only reducing the feeling of nausea but also improving appetite.

Hangovers are also known to cause ear-splitting headaches, and CBD works quite effectively as a painkiller. Again, the cannabis extract works by interacting with the endocannabinoid nervous system uniquely. A review published in the June 2019 issue of Current Opinion in Neurology suggested that cannabidiol can affect the function and activity of the neural pathways that are responsible for pain control. The review also states that CBD can suppress the release of chemokines and cytokines, which are associated with inflammatory pain.

Yes, CBD can help manage hangovers. The compound has powerful anti-inflammatory and anti-nausea properties that reduce nausea, vomiting, and headaches. However, the FDA hasn’t yet approved it as a medication, so be sure to consult your doctor before use.

Industry watchers strongly believe that CBD companies like Grapefruit Boulevard Investments Inc. (OTCQB: IGNG) and Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) aren’t surprised that the scientific community is confirming more benefits of CBD as the years go by.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

$BHAT Announces Launch of “Talking Tom and Friends” Bouncing Bubble in China

$YGYI to Host Conference Call to Review 2019 Q3 and Nine-Month Results

$SRAX Outlines BIGtoken, Company Strategy at Microcap Rodeo Investor Conference

$OGI Honored w/ Top Product Award in High THC Oil at 2019 Canadian Cannabis Awards

$LXRP Colorado Now Has to Modify Its Rules to Meet Federal Requirements

November 11, 2019

Hemp farmers all over the country can finally heave a sigh of relief after the U.S. Department of Agriculture released its long awaited interim final rule on hemp. Senator Cory Gardner applauded the USDA soon after the regulations were announced, thanking it for “moving forward on hemp rulemaking and recognizing hemp production as an agricultural activity.” He said that legal hemp has the potential to be a major boon to agricultural communities across Colorado, giving farmers another viable and profitable option for their fields.

However, farmers in Colorado haven’t yet celebrated the news. Even though the Colorado Department of Agriculture has said it intends to submit a new hemp plan to the USDA in 2020, the state of Colorado had already implemented its own state plan on hemp long before it was legalized at the federal level in December 2018.

According to Shawn Hauser, a hemp attorney with Vicente Sederberg, the state will have to alter some of its hemp regulations to align more closely with the USDA regulations. She adds that it could result in more restrictive rules than the ones Colorado hemp farmers are accustomed to. For example, they will be subject to stricter testing requirements for THC levels, and there will be less opportunity to mitigate hot hemp (hemp with more than the federally set 0.3% THC limit).

“Federal rules are pretty strict with requiring hot hemp to be destroyed by a DEA agent. There is no opportunity for remediation or correction. The way the federal regulations are set up, they’re going to affect every state significantly,” she says, adding that “the testing and sampling specifically are different from what most states have in practice.”

The new regulations require 100% of all hemp harvests to undergo THC testing in labs certified by the Drug Enforcement Administration. Hauser argues that Colorado’s Agriculture Department has only enough bandwidth to test about 25% of the current hemp harvests, and that there aren’t enough DEA certified labs to test the entire crop anyway. This means that there could be delays in harvesting hemp as farmers wait for THC test results from the few approved facilities.

The rules were implemented with effect from October 31, and they will be replaced in two years with the final rules. States have a year to either send in their own proposals for hemp regulation or ban the crop altogether. According to Hauser, the CDA’s Colorado Hemp Advancement and Management Plan (CHAMP), a committee created by Governor Jared Polis, will send Colorado’s hemp proposal to the USDA.

A public comment period is currently underway for all interested parties to give their opinions on the USDA’s regulations. Analysts think hemp companies like HTC Extraction Systems (TSX.V: HTC) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) anticipate some supply shocks as these rules kick in next planting season, but the overall outlook is optimistic.

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

HempWireNews is part of the InvestorBrandNetwork.

$GGBXF Can You Increase Your Metabolism and Lose Weight Using CBD?

November 11, 2019

It would be safe to say that there has not been a medicine, pharmaceutical or natural, as potent and versatile as cannabidiol (CBD). Over the years, plenty of anecdotal evidence has surfaced, claiming the cannabis extract is quite effective against a host of diseases ranging from high blood pressure and anxiety to chronic pain. In June 2018, the FDA approved a CBD-based drug to treat seizures in rare and severe forms of childhood epilepsy.

Now, the non-psychoactive cannabis extract may have another useful notch added to its list of benefits. Despite cannabis being known for increasing appetite, current findings show that CBD may also be able to aid in weight loss. So, can CBD really help you lose weight? The answer is yes, and it does that by uniquely acting on the body.

The body has an endocannabinoid nervous system, and this system responds to different compounds in the body through two cannabinoids (CB) receptors, termed the CB1 and CB2 receptors. CB1 receptors are mostly located in the brain and central nervous system, while CB2 receptors exist throughout the body.

Obese people tend to have more widespread CB1 receptors, especially in the fatty tissue, and this has led researchers to believe that there may be a link between obesity and the activation of CB1 receptors. Overstimulation of the CB1 receptors results in an increased risk of metabolic syndrome characterized by excess belly fat, high blood sugar levels, high triglyceride levels, and high cholesterol levels.

CBD does not activate the CB1 receptors. Instead, it influences the body’s natural cannabinoids to either block or deactivate the receptors. In this regard, researchers say it may help in weight loss. Research has also shown that CBD can affect metabolism. It boosts the number and activity of mitochondria, increasing the body’s ability to burn calories, on top of converting excess white fat into brown fat.

White fat is responsible for storing energy and insulating and cushioning your organs. In excess, it leads to conditions such as heart disease and diabetes. Brown fat, on the other hand, generates body heat by burning to release calories. Leaner people tend to have more brown fat than overweight people. Regular exercise and adequate sleep will also convert white fat to brown.

Based on CBD’s effect on metabolism, we can say that it can, in fact, aid in weight loss. However, all the weight loss studies were carried out on animals, and there is no current research on whether it is an effective weight loss solution for humans.

That notwithstanding, it is believed that CBD industry players like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and Dama Financial wouldn’t be surprised if human trials confirm that CBD can aid weight loss while boosting metabolism.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

$GWPD Announces Launch of “Prolific Soilless Growth Medium” and “Prolific Hydro” on Amazon

$YGYI CBD Dispensing Robots Installed in Colorado

November 8, 2019

CBD is probably the breakout medicine of the century. Dubbed by some as a wonder drug, the cannabis extract has been found capable of alleviating a variety of medical conditions ranging from chronic pain, anxiety, and high blood pressure to rare forms of epilepsy in children. Quite naturally, demand for CBD products has boomed, with industry players estimating that the industry will be worth $23.7 billion by 2023 in sales alone.

7-Eleven has joined the fray, and they have come up with a radical idea. The convenience store chain will soon roll out CBD-dispensing robots in its Colorado stores, and customers will be able to buy CBD products via a touchscreen, a process that won’t take more than 3 minutes. They will also entertain and educate customers on the benefits of CBD products. Greenbox Robotics developed the artificial intelligence (AI) powered robots.

According to Zack Johnson, founder and CEO of Greenbox Robotics, Greenbox makes it easy to discover, select, and purchase cannabis and CBD products via self-service robot locations. “We are bringing a $55 billion-plus industry over the counter with a simple consumer touch.” He adds that Greenbox Robotics inspects and approves every product before placing it inside its robots.

Boulder and Denver are the first cities in the state to receive the CBD-dispensing robots, with one store near the University of Colorado Campus and another at Fox Theatre in Boulder. Kenneth Monfort, the owner of the Boulder and Colorado locations, says that he believes that adding Greenbox to the 7-Eleven stores will add value, intrigue, and delight their customers while reducing shrinkage. “We trust Greenbox to curate the CBD collection we offer our customer base,” he adds.

This is part of Monfort and Greenbox’s pilot program. They hope to roll out robots in more locations across the state. “What we’re looking for is to generate sales and show 7-Eleven corporate that this is a value add, we’re introducing a product that is protected, not on shelves to risk theft, but we are also looking to generate sales for you in your store beyond just the CBD product,” says Greenbox Robotics CEO Zack Johnson.

The robots are used to dispense a variety of CBD products and strains of marijuana all over the state. The robots will also monitor and collect information on product shelf life and purchasing trends that will help them better understand customers and their preferences.

Industry watchers believe that CBD companies like IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) and Youngevity International Inc. (NASDAQ: YGYI) see the robots dispensing CBD as a sign that ordinary shoppers have embraced CBD, which is a good thing for the future of the industry.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

$POAI Presents Initial Findings from Analysis of Landmark UK 100,000 Genomes Project

November 8, 2019

$OGI It’s Time to Buy Cannabis Stocks, Says 1 Wall Street Firm

With pot stocks at two-year lows, two stand out as no-brainer buys, according to this 74-year-old investment company.

At this time last year, marijuana was considered to be the hottest investment trend on Wall Street. That’s because it was projected to be one of the fastest growing industries over the next decade. Although estimates on Wall Street vary wildly, the expectation is that legal weed sales would grow to between $50 billion and $200 billion annually in roughly a decade’s time.

Unfortunately, things haven’t gone as planned, and over the past seven months, we’ve witnessed marijuana stocks go up in smoke. The Horizons Marijuana Life Sciences ETF, which contains more than five dozen cannabis stocks of various weightings, has shed 50% of its value since the end of the first quarter, with a number of very prominent pot stocks performing even worse.

To our north, Canada has been hampered by regulatory and procedural issues. Health Canada has been unable to keep up with a backlog of cultivation and sales licensing applications, while certain provinces have only approved a handful of retail store licenses. Meanwhile, in the U.S., high tax rates have encouraged the illicit market and made it very difficult for the legal cannabis to compete against the black market on price.

But things may be about to change, at least according to 74-year-old Wall Street firm Cantor Fitzgerald.

Marijuana stocks have found a bottom, and these two pot stocks are buys

On Tuesday, Cantor’s covering analyst, Pablo Zuanic, published a note on the industry and initiated coverage on six cannabis stocks. In that note, Zuanic emphasized that marijuana stocks were now at two-year lows, which seemed attractive based on their long-term opportunity. In particular, Cantor Fitzgerald sees value in Canadian marijuana stocks, especially with the coming launch of derivatives in mid-December. Zuanic also highlights the continuing acceleration of recreational sales, and ongoing dispensary openings, as catalysts for higher valuations.

Which stocks should you buy? According to Zuanic, OrganiGram Holdings (NASDAQ:OGI) and Aphria (NYSE:APHA) were the two to receive an overweight rating.

New Brunswick-based OrganiGram was initiated with an overweight rating and a price target of 17 Canadian dollars. That represents upside of — get this — almost 300% from the prior day’s closing price. OrganiGram is certainly poised to benefit from the launch of derivatives, with the company spending CA$15 million on a line of fully automated equipment capable of producing 4 million kilos of infused chocolates per year. OrganiGram also developed a proprietary nano-emulsification technology that expedites the onset of cannabinoids and can be added to beverages.

Furthermore, OrganiGram is the first licensed producer to have generated a no-nonsense operating profit. If you strip out fair-value adjustments and a host of other derivative liability revaluations, no other producers have been able to turn a genuine quarterly operating profit, save for OrganiGram.

As for Aphria, Zuanic and his team placed a CA$10.40 price target on its stock. This implies about 55% upside from the prior day’s closing price. In particular, Cantor Fitzgerald favors Aphria’s discount to its peers, even when adjusting for the company’s German distribution business, which is a low-margin operation. Zuanic is also confident in management, which has forecast CA$1 billion in revenue for fiscal 2020.

Wait and see with these three big names

If OrganiGram and Aphria are buys, what about the most popular pot stocks in the world: Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB), and Tilray (NASDAQ:TLRY)? According to Cantor Fitzgerald, all three have question marks that have them rated as “neutral” for the time being.

Canopy Growth, the largest marijuana stock in the world, by market cap, had its price target set at CA$27 by Zuanic and his team. This represents just 2% upside from the previous day’s close. The issue with Canopy Growth is that it has the industry’s worst margins, and hasn’t done a very good job of monetizing its impressive medical intellectual property portfolio, especially in Canada, per Zuanic. I’d also add that Canopy Growth is without a permanent CEO at the moment, and has seen its goodwill swell to more than 22% of total assets. In short, I wholeheartedly agree with Cantor Fitzgerald’s assessment to watch and wait on Canopy Growth.

As for Aurora Cannabis, it was tagged with a price target of CA$5.10, representing about 8% upside from where it closed on Monday. Interestingly, Zuanic expects Aurora to rally in the months that lie ahead, but sees more opportunity in other Canadian pot stocks. Remember, Aurora Cannabis has close to CA$3.2 billion in goodwill on its balance sheet after an aggressive acquisition spree. This represents 58% of its total assets and makes it very likely that a writedown is in its future. Caution certainly seems merited.

Lastly, Tilray was given a $20 price target (that’s U.S.), implying downside of 10%. Similar to Aurora, Zuanic believes Tilray could rally in the months to come, but foresees more attractive pot stocks to buy. Tilray’s biggest issue just might be that it lacks a clear-cut strategy. After CEO Brendan Kennedy announced plans in March to de-emphasize Canada in favor of European and U.S. investment, it’s become unclear what the next steps will be for Tilray in managing its expenses and pushing toward operating profitability.

The one marijuana stock you should avoid

Out of the half-dozen cannabis stocks that Cantor Fitzgerald initiated coverage on this week, it’s Quebec-based HEXO (NYSE:HEXO) that gets the lone red mark. HEXO was initiated as an underweight (the equivalent of sell) with a price target of CA$2.40. This represents potential downside of 12% from where its shares closed on Monday.

According to Zuanic, HEXO has lofty goals that have helped push the company’s valuation higher, but these goals aren’t aligned with the company’s vision. As a reminder, HEXO readjusted sales expectations for the fiscal fourth quarter just a few weeks before delivering its Q4 report. Rather than a doubling in sequential quarterly revenue, HEXO warned investors that growth would come in at about 19%, at the midpoint of its range. The company blamed the slow rollout of physical dispensaries, early pricing pressures, and the delayed launch of derivatives for its sales disappointment.

What’s more, HEXO also announced that it was cutting 200 jobs across a variety of departments, as well as idling production at the Niagara facility. HEXO certainly has some serious challenges to contend with, but I don’t see it as being any worse off than Canopy, Aurora, or Tilray, all of which have significant issues to contend with of their own.

$SRAX to Host November 13 Conference Call to Review Q3 2019 Financial Results

$POAI Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine

November 7, 2019

$CNPOF $RIV.V Portfolio Companies Prepare for Cannabis 2.0

TORONTO, Nov. 7, 2019 – As cannabis 2.0 rolls out across Canada, several Canopy Rivers Inc. (“Canopy Rivers“) (TSX: RIV, OTC: CNPOF) portfolio companies are positioning themselves to seize new opportunities after a series of recent announcements. These include two Health Canada licence amendments enabling certain portfolio companies to process and sell edibles, extracts, and topicals for the Canadian market. Additionally, a portfolio company signed an agreement with Canopy Growth Corporation (“Canopy Growth“) (TSX: WEED, NYSE: CGC), demonstrating the benefits facilitated by Canopy Rivers’ relationship with Canopy Growth.

• TerrAscend Corp. (“TerrAscend“) (CSE: TER, OTCQX: TRSSF), the first and only global cannabis company licensed for sales in Canada, the U.S., and the E.U., received an amendment to its licence from Health Canada allowing it to process and sell cannabis edibles, extracts, and topicals produced at its EU-GMP certified facility in Mississauga, Ontario. Pending Health Canada’s authorization, TerrAscend expects to begin sales of its new product formats in December 2019.
• James E. Wagner Cultivation Corporation (“JWC“) (TSXV: JWC) received a Health Canada licence amendment allowing it to process and sell cannabis edibles, extracts, and topicals at its Kitchener, Ontario pilot facility. The approval is an important development as JWC works towards introducing its derivative line of cannabis extract products – including kief, rosins, and pre-rolls – in the first quarter of 2020.
• Radicle Medical Marijuana Inc.’s Clementine Purp, Orange CKS, Strawberry Fire OG, and The OG products are now available through Spectrum Therapeutics’ (“Spectrum“) online distribution platform. Spectrum is Canopy Growth’s international medical brand, serving as the company’s healthcare professional and patient-facing identity in medical markets in Canada and around the world.

About Canopy Rivers:

Canopy Rivers is a venture capital firm specializing in cannabis. Its unique investment and operating platform is structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers and its portfolio companies with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the expectation that TerrAscend will begin sales of its new product formats in December 2019; JWC’s plan to introduce its derivative line of cannabis extract products in the first quarter of 2020; and expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in the timing of, and plans for, the product lines of TerrAscend and JWC; changes in consumer preferences and demands; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

$YGYI Granted Registered Hemp Seed Dealer License in the State of Florida

Khrysos Industries to Begin Tissue Cultures and Seed Production Immediately with Marketable Tissue Cultures and Seed Production Available for Sale Q2 of 2020

SAN DIEGO, Nov. 7, 2019 — Khrysos Industries, Inc. a wholly owned subsidiary of Youngevity International, Inc. (NASDAQ: YGYI), a multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise and its expanding commercial hemp enterprise, announced today that Florida’s Agricultural Environmental Services Bureau of Licensing and Enforcement has granted Khrysos Industries a Hemp Seed Dealer License.

“Khrysos Industries, in anticipation of being granted the seed dealer license, has already purchased Six 45 X 8 Hemp Seed Grow Houses complete with auto temperature and humidity-controlled systems with all houses containing UV lighting systems and automated irrigation.  These automated climate control grow houses all are housed with dehumidification systems and will be located on our 45-acre tract of land in Central Florida,” said Dr. Dwayne Dundore, President of Khrysos.

“We are proud to be granted this Seed Dealer License by the Florida Department of Agriculture,” said Dave Briskie, President and CFO of YGYI, about its wholly owned subsidiary Khrysos Industries.  “I am anxious to see Aftab A. Khan, put his PHD in plant breeding and genetics from Cornell University along with his 25 plus years of experience in plant breeding, genetics, molecular biology and biochemistry to work in leading this division of our company.  We believe his expertise in genome editing, tissue culture production, clonal propagation, and seed production provides us with an opportunity to take a leading role in the Hemp Industry.”

About Khrysos Industries, Inc.

Khrysos Industries is a leading manufacturer of commercial hemp-based CBD extraction, post processing equipment, and end-to-end processor of CBD isolate, distillate, water soluble Isolate, and water-soluble distillate. Its subsidiary, INX Laboratories provides a broad range of testing services including potency analysis for its supply partners of hemp derived CBD products. Khrysos provides hemp growers, feedstock suppliers, and CBD crude oil producers the use of equipment, intellectual capital, production consultancy, tolling services, and wholesale CBD channel sales capabilities. Khrysos Industries was acquired by Youngevity International (NASDAQ: YGYI) on February 12th, 2019. Be sure to visit us at khrysosglobal.com, like us on Facebook and follow us on Twitter, or contact us at info@khrysosglobal.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions and includes statements regarding  the expertise of Aftab A. Khan, in genome editing, tissue culture grow, clonal propagation, and seed production providing an opportunity to take a leading role in the Hemp Industry. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, our ability to take a leading role in the Hemp Industry, our ability  to improve our profitability, expand our liquidity, and strengthen our balance sheet, our ability to continue to maintain compliance with the NASDAQ requirements, the acceptance of the omni-direct approach by our customers, our ability to expand our distribution, our ability to continue our financial performance and the other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018 and our subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-Kand the other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018 and our subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contacts:

Youngevity International, Inc.
Dave Briskie
President and Chief Financial Officer
1 800 982 3189 X6500

Investor Relations
YGYI Investor Relations
800.504.8650
investors@ygyi.com

$GGBXF The 9 Best Marijuana Stocks in October

True to Halloween, October was another ghoulish month for cannabis stocks. After rocketing higher during the first quarter of the year, marijuana stocks have been in a precipitous seven-month downtrend. Last month, a majority of pure-play pot stocks ended the month lower, with the Horizons Marijuana Life Sciences ETF, the first exchange-traded fund focused on marijuana, losing another 12%. Since the end of March, this popular ETF has lost 50%, inclusive of dividends paid.

October featured many of the same concerns that have plagued the North American pot industry over the past year — namely, the exceptionally slow rollout of physical dispensaries in Canada (along with a slow licensing process) and high tax rates in select U.S. states curbing legal sales channels.

These are, unquestionably, the top pot stocks for October

However, a small handful of cannabis stocks managed to buck October’s weakness. Excluding a handful of brand-name stocks that are merely dipping their toes into the cannabis pond, the following nine pot stocks ended the month higher by a double-digit percentage (listed in descending order, and rounded to the nearest percentage point):

• KushCo Holdings (OTC:KSHB): Up 35%
• Liberty Health Sciences: Up 32%
• Trulieve Cannabis (OTC:TCNNF): Up 24%
• MediPharm Labs (OTC:MEDIF): Up 23%
• Green Growth Brands (OTC:GGBXF): Up 22%
• CV Sciences (OTC:CVSI): Up 20%
• iAnthus Capital Holdings: Up 16%
• GW Pharmaceuticals: Up 16%
• Greenlane Holdings: Up 16%

What allowed this group of cannabis stocks to outperform while the rest of the industry went up in smoke? Let’s take a closer look.

Profitability is being rewarded

For starters, it shouldn’t come as a surprise that investors are rewarding profitability. In a space where losses are common, multistate operator Trulieve Cannabis, extraction-services provider MediPharm Labs, and hemp-based cannabidiol (CBD) products company CV Sciences are all currently profitable.

In particular, Trulieve Cannabis has really stood out with its bottom line. Based in Florida, Trulieve has opened 38 stores in its home state. Keeping its costs close to the vest, so to speak, has allowed Trulieve to effectively market its medical marijuana products, as well as build its brand. This allows it to report an operating profit without the one-time benefits that other pot stocks have leaned on to generate a profit. While it’s possible that Trulieve’s margins will get pinched a bit as competition in Florida intensifies, and as it builds up its brand in states like California and Massachusetts, there’s little concern about the company remaining profitable.

Encouraging operating results fuel marijuana stocks higher

As noted, most marijuana stocks aren’t profitable. However, some are at least demonstrating progress with their operating results — and that’s being rewarded by Wall Street more often than not.

Last month, cannabis-infused products manufacturer and multistate retail operator Green Growth Brands reported its fourth-quarter operating results. Sales in the fourth quarter totaled $7.2 million, representing a 29% increase from the sequential third quarter, with CBD revenue rising by 271% on a sequential quarterly basis to $1.7 million. I know that doesn’t sound like a lot in the way of sales, but remember that CBD-infused products bear juicy margins, and that Green Growth is still in the early stages of rolling out its storefronts to take advantage of CBD sales.

Having also recently resolved any near-term financing concerns with a bought-deal offering, investors appear willing to cut Green Growth Brands some slack as long as its high-margin CBD product growth continues.

Investors flocked to safer derivative plays

Aside from profitability, Wall Street and retail investors are also seeking out signs of predictability in a very unpredictable space. That’s why MediPharm Labs and CV Sciences likely found buyers in October.

MediPharm has already landed a number of promising extraction contracts with major Canadian growers, including Cronos Group. What makes these contracts so attractive is that they’re often for a period of 18 to 36 months. This ensures MediPharm will be generating relatively predictable cash flow, which also allows the company to moderate its costs and remain profitable. Despite beginning operations in November 2018, the company already turned a nominal per-share profit in the second quarter.

Something similar could be said for CV Sciences. Despite a somewhat checkered past that looks to be holding back its valuation a bit, the company is poised to benefit from growing demand for CBD products. In recent months, CV Sciences landed a retail distribution deal with Kroger spanning 1,350 stores in 22 states, as well as a more-than-500-store deal with Vitamin Shoppe.

Value, perhaps?

Lastly, we may be seeing the first bit of value hunting in the marijuana space. KushCo, for instance, was the top-performing pot stock in October, with a gain of 35%. This follows a September that saw it deliver some of the worst returns among the five dozen weed stocks I follow.

KushCo has been hammered because of its reliance on vaporizers for a majority of the company’s current sales. These vaporizers have been hit by tariffs associated with the U.S.-China trade war, and they’re also a source of concern in the U.S., where the Centers for Disease Control and Prevention has 1,888 confirmed or probable cases of mystery lung illnesses caused by vaping over the past three months.

However, KushCo is now valued at less than one time next year’s sales, and KushCo’s management team has reaffirmed its 2019 sales guidance on a number of occasions. Although profitability is still a couple of years away, value seekers might be intrigued by KushCo’s top-line growth and its numerous avenues to ancillary revenue.

$TGODF to Release Q3 2019 Financial Results on November 14

$SRAX Empowering Consumers to Profit from Personal Data, Protect Privacy

• Growing awareness by public about how big companies track, sell personal data
• Owning, monetizing personal data possible through BIGtoken app
• Working to educate consumers on how to protect, own use of personal data

People are starting to understand how vulnerable their data is and how big companies such as Facebook, Twitter, Snapchat and other social-media platforms track and sell that data. Every individual creates data by what they search, view, read, listen to, purchase and like. That data is collected and sold, generating billions in revenue each year. SRAX Inc. (NASDAQ: SRAX), through its BIGtoken platform, is placing power of that data back into an individual’s hands. Through SRAX, consumers can now own and monetize their personal data.

In spring 2018, the European Union’s General Data Protection Regulation (GDPR) set guidelines that caused online companies worldwide with audiences in the EU to scramble for compliancy. While the United States doesn’t currently have the same restrictions, things are beginning to change. The California Consumer Privacy Act (CCPA) will go into effect Jan. 1, 2020. This new law will give consumers the ability to forbid a company from…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

$LXRP DehydraTECH Drug-Delivery Platform May Ease Overdose Risk in Cannabis Edibles

• Edible cannabis products are absorbed slowly
• Consumers of cannabis edibles often mistake the delayed effect for insufficiency, leading to overdosing
• DehydraTECH drug-delivery platform speeds up absorption, reducing overdose risk

Sometimes what is gained on the roundabouts is lost on the swings, to paraphrase an old saying. Cannabis liberalization has introduced an entirely new sector to the food and beverage industry – namely, cannabis edibles such as cookies, chocolates and candies. It’s a sector that appears poised for growth. But as mass consumption increases, a hidden problem is emerging (http://cnw.fm/JwQv3). Because bioabsorption rates via edibles are slower than those via smoking, oral ingestion is leading to unexpected challenges. Consumers mistake the slow onset of effect of traditional cannabis edibles for not enough cannabinoid, so they increase consumption which can lead to overdosing. However, a biotech solution from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) appears to solve this problem. The company’s DehydraTECH(TM) drug-delivery platform greatly increases the rate at which drugs like cannabis are absorbed by the body. The technology could be used to avoid overdoses before they ever begin.

Consumers have certainly developed a taste for cannabis. A recent report projects the global cannabis-edibles market will reach over $11.6 billion by 2025, climbing at a CAGR of 25 percent, from $2.4 billion in…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

$OGI Support for Cannabis Continues to Rise Among Consumers and Retailers

November 6, 2019

Palm Beach, FL – November 6, 2019 — Cannabis growth is expected to be incredibly explosive.  All thanks to incredible demand from consumers.  In the U.S. alone, 61% of Americans support the legalization of cannabis, according to the General Social Survey conducted by NORC at the University of Chicago.  That’s up from just 57% in 2016. Even retailers are waking up to sizable growth and demand.  Neiman Marcus, Abercrombie & Fitch, Vitamin Shopper, Kroger’s, Barney’s, DSW, CVS, American Eagle Outfitters, Sephora, and Walgreen’s are all carrying CBD products.  That’s leading to a wide range of opportunity for companies including Veritas Farms Inc. (OTCQB:VFRM), Aphria Inc. (NYSE:APHA) (TSX:APHA), Green Thumb Industries Inc. (CSE:GTII) (OTCQX:GTBIF), OrganiGram Holdings Inc. (TSX-V:OGI) (NASDAQ:OGI), and CV Sciences Inc. (OTCQB:CVSI).

Veritas Farms Inc. (OTCQB:VFRM) BREAKING NEWS: Veritas Farms Inc. just announced that its ingestible and topical products will be featured in 152 South Eastern Grocers’ Winn Dixie stores in Florida and South Carolina. Veritas Farms full spectrum hemp oil products available at Winn Dixie include tinctures, capsules, gummies, salves, lotions and pet tinctures.  Alexander M. Salgado, CEO and co-founder of Veritas Farms, commented, “We are excited to grow our chain grocery presence with South Eastern Grocers in their Winn Dixie brand of grocery stores. As a highly regarded grocery retailer, their entrance into the full spectrum hemp oil category with Veritas Farms further signals the growing significance of the category and Veritas Farms ability to capitalize on chain retail opportunities.” Mr. Salgado concluded “We look forward to working with and supporting Winn Dixie’s full spectrum hemp oil category.”

Other cannabis-related developments from around the markets include:

Aphria Inc. (NYSE:APHA) (TSX:APHA) announced it has received a cultivation licence from Health Canada for Aphria Diamond, the Company’s second Leamington, Ontario cannabis greenhouse facility, bringing an additional 1,300,000 square feet of production space with an annual growing capacity of 140,000kg. Combined with the Company’s Aphria One facility and its subsidiary Broken Coast Cannabis, the Company now has more than 2,400,000 square feet of cultivation space capable of reaching a total annualized production capacity of 255,000kg.  “We are extremely pleased to receive the licence for our long-awaited Aphria Diamond facility, which more than doubles our Canadian production capacity,” said Irwin D. Simon. “Reaching industry-leading production levels coinciding with the expansion into new categories and new opportunities for cannabis in Canada and around the world is a transformative moment for Aphria Inc.”

Green Thumb Industries Inc. (CSE:GTII)(OTCQX:GTBIF) announced that GTI Founder and Chief Executive Officer Ben Kovler will participate in a panel discussion and one-on-one meetings at the Cowen 2^nd Annual Boston Cannabis Conference on Tuesday, November 12, 2019.

OrganiGram Holdings Inc. (TSX-V:OGI)(NASDAQ:OGI) announced that the Company was recognized at the Excellence in Manufacturing Consortium Awards of Excellence ceremony in Toronto on October 9. Organigram was honored with an Outstanding Member Contribution Award for delivering exemplary support to the EMC over the course of the Company’s membership. The award, accepted by Organigram Senior Vice President of Operational Services, Jeff Purcell, recognizes organizations which demonstrate outstanding achievement in manufacturing. “Producing high-quality cannabis in a state-of-the-art indoor environment, Organigram operates in an interesting cross-section of horticulture, consumer packaged goods and manufacturing,” Purcell said. “We are very proud to accept this award and support EMC, a group that sets the standard for manufacturing excellence in Canada.”

CV Sciences Inc. (OTCQB:CVSI) announce its support of the U.S. Department of Agriculture’s (USDA) progress on implementation of the hemp provisions of the 2018 Farm Bill. On October 29, 2019, U.S. Secretary of Agriculture Sonny Perdue announced the interim final rule for the U.S. Domestic Hemp Production Program. USDA regulation of hemp farming provides  a consistent regulatory framework that supports responsible and sustainable hemp production in the United States. A strong USDA regulatory framework is needed to differentiate hemp, an agricultural commodity, from marijuana, a controlled substance, and to protect farmers and consumers.  USDA announced that later this week, an interim final rule formalizing the program will be published in the Federal Register. This will allow hemp to be grown under federally-approved plans and make hemp producers eligible for agricultural programs, like crop insurance. The rule includes provisions for USDA to approve hemp production plans developed by states and Indian tribes including: requirements for maintaining information on the land where hemp is produced; testing the levels of THC to ensure compliance with the law; disposing of noncompliant plants; and licensing requirements. “We are eager to see full implementation of USDA’s Hemp Production Program,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “The hemp industry is poised for rapid growth that will create new jobs and economic development opportunities for farmers, rural communities and the CBD industry. Regulatory clarity is critical for the hemp industry and we believe the interim final rule is another step toward the proper regulatory framework that will help unlock the true domestic growth potential of the industry. We’d like to thank the U.S. Hemp Roundtable and its hemp industry members for their tireless efforts in achieving this milestone. Now that hemp farming regulations have been established it’s time to focus on FDA’s work to clarify the regulatory pathway for hemp-derived CBD products in dietary supplements. USDA and FDA regulation of hemp and CBD will provide a level playing field for quality and science-based CBD companies to operate, and allow consumers access to safe and beneficial products.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated thirty five hundred dollars for news coverage of current press releases issued by Veritas Farms Inc., by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

$POAI Featured in Publication Discussing the Impact of AI on Cancer Treatment

NEW YORK, Nov. 06, 2019 — via NetworkWire — Predictive Oncology (NASDAQ: POAI) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, titled “New Hope in the Battle Against Ovarian Cancer,” visit: http://nnw.fm/ncAI8

Ovarian cancer is difficult to treat and lethal, with survival rates much lower than other cancers that affect women. Recently, the battle against ovarian cancer has shifted strategy, and new optimism has come to the fore.

Predictive models using artificial intelligence on large data sets of patient drug-treatment protocols and historical outcomes are now providing actionable intelligence for pharma to develop targeted therapeutics and for oncologists to prescribe the best course of treatment to improve individual patient outcomes. Predictive Oncology (NASDAQ: POAI) (POAI Profile) is laser focused on providing the molecular information critically needed to improve the lives of women stricken with ovarian cancer. The company has begun sequencing ovarian cancers as part of its CancerQuest2020 project and is building the largest ovarian multi-omic database in the world, designed to speed the development of new drugs and provide better therapeutic choices. The rest of pharma is also racing to find solutions.

About Predictive Oncology Inc.

Predictive Oncology is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow. Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, with more than 38,000 specific to ovarian cancer. The company’s data is highly differentiated, having both drug-response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development. For more information, visit the company’s website at www.Predictive-Oncology.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

$TGODF Giant Breakthroughs with Psychedelics Creating Big Investment Opportunities

November 5, 2019

Palm Beach, FL – November 5, 2019 — Research into psychedelics for the treatment of anxiety, depression, and other mental illnesses has only begun to expand – and investors are excited.  Studies have already shown that when it’s “ingested it transforms into a psychoactive chemical in the body that might help dramatically reduce symptoms of depression, messing with the brain’s pre-frontal cortex, which affects our mood and perception of things and another part of your brain, that’s a part of processing emotional reaction to fear and anxiety,” as reported by Spectrum News. Plus, in recent months, Johns Hopkins Medicine announced the launch of the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression.  Psychiatrists at Johns Hopkins University even found that mushrooms can help with smoking cessation, and another study found it can assist with alcohol dependence, for example.  Researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.  Better, over the last year, Denver, Colorado, and Oakland, California decriminalized the possession of products containing psilocybin or psilocin.  As excitement builds, it’s opening a range of opportunity for companies that have already established launching cannabis products including The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), The Green Organic Dutchman (TSX:TGOD) (OTCQX:TGODF), Canopy Growth Corporation (TSX:WEED) (NYSE:CGC), The Supreme Cannabis Company Inc. (TSX:FIRE) (OTCQX:SPRWF), and Flowr Corporation (TSX-V:FLWR) (OTCPK:FLWPF).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced that on November 4, 2019 it entered into a definitive agreement to license 126 formulas based on ancient Ayurvedic medicine to its wholly owned subsidiary Flourish Mushroom Labs for use in products infused with functional or magic mushrooms for a 50 year term. The Yield Growth licensed formulas include skin care formulas such as face masks, body oils, creams, face oils, exfoliants, food and beverages formulas such as teas, ayurvedic herbal blend formulas,  and other wellness formulas for the purpose of developing, manufacturing, marketing and selling  products worldwide, excluding Canada. The formulas may be used in foods, beverages, personal care, skin care, cosmetic and other wellness products that are infused with functional mushrooms or psilocin or psilocybin (magic mushrooms) or any combination thereof. In consideration for the non-exclusive 50 year license, Flourish Mushroom Labs has agreed to pay $3,000,000 to Yield Growth. The fee is payable  as follows: $1,800,00 payable as 90 million common shares of Flourish Mushroom Labs to be issued to Yield Growth at a deemed value of $0.02 per share, which shall be subject to escrow provisions pursuant to NP 46-201.  The remaining sum of $1,200,000 may be paid in cash over 24 months, but if Flourish Mushroom Labs is successful in listing its stock on a Canadian stock exchange under the symbol “MUSH”, which symbol has already been reserved, within 6 months, then $200,000 shall be deducted from the purchase price, and if a listing is achieved between 6 – 12 months, then $400,000 shall be deducted from the purchase price. This acquisition by  Flourish Mushroom Labs adds to its existing catalogue of mushroom based coffee, teas, elixirs, soups and other edibles. Flourish Mushroom Lab  intends to begin commercialization of its extensive catalogue with mushroom-based soups and coffees. “We are positioning Flourish Mushroom Labs to be a key player in the fast growing international functional mushroom market,” says Penny White, Yield Growth CEO. “Flourish Mushroom Labs also acquired the rights to infuse the  products in its newly acquired formulas with psychedelic mushrooms, where it’s legal to do so.”

Other cannabis-related developments from around the markets include:

The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF) unveiled a new strategic plan, including a series of actions to reduce the Company’s financing requirements while maintaining its path to profitability. These actions will result in increased agility, lower capital requirements and an optimal production capacity to serve the organic segment. “These actions are logical next steps in TGOD’s road to profitability. While we are committed to – and our strategy continues to leverage – our unparalleled scale as an organic producer as well as our international assets, we have identified areas where our scale would not provide for meaningful returns in the near term given the slower pace of legal market conversion. We will optimize our operating efficiency by deferring excess capacity and expenses, whether they center on production facilities, international expansion projects or technology,” commented Brian Athaide, CEO of TGOD. Given current market conditions, the Company is adopting a new construction and operating plan to reduce its cash needs, with a prudent production ramp leading to expected positive operating cash flow in Q2 2020. The Ancaster greenhouse is complete, and the Ancaster processing facility is approximately five weeks from material completion. TGOD’s large scale project in Valleyfield, Quebec will be demarcated into smaller phases, with more to be completed once the market further develops.

Canopy Growth Corporation (TSX:WEED)(NYSE:CGC) announced updates on key developments in the United Kingdom and Luxembourg. In these countries, the Company’s pharmaceutical business, Spectrum Therapeutics, continues to expand its sophisticated, pan-European cannabis production and distribution network serving the needs of physicians and their patients. Canopy Growth is committed to transforming healthcare in Europe by providing better access to medical cannabis treatments that have the potential to improve the lives of millions of patients. In the UK, Spectrum Therapeutics has received licenses from the Medicines and Healthcare products Regulatory Agency (“MHRA”) and Home Office to store and distribute cannabis-based medicinal products (“CBMPs”). The first of its kind facility in the UK is designed to reduce prescription delivery time, a key development as the company establishes its footprint in the UK. The license also allows the company to import CBMPs to the UK directly from Spectrum’s European and global networks, optimizing its supply chain and reducing overheads, without need for third-party suppliers.  Spectrum Therapeutics has become the exclusive supplier of medical cannabis to the Grand Duchy of Luxembourg (“Luxembourg”). The contract will see Luxembourg receive medical cannabis from Spectrum’s licensed facilities in Denmark and around the world until December 31, 2021. In 2018, the Government of Luxembourg unanimously passed a law to decriminalize medical cannabis for patients with severe unmet needs. Under the new legislation, general practitioners and specialist medical professionals who have undertaken specific training are able to prescribe cannabis to eligible patients in Luxembourg. Patients with severe needs include those living with cancer, neuro-degenerative, chronic and painful diseases. “We are proud to share news of this decision from the government of Luxembourg, connecting patients to medicine supplied through our European platform,” said Paul Steckler, Co-Managing Director of Europe, Canopy Growth.

The Supreme Cannabis Company Inc. (TSX:FIRE)(OTCQX:SPRWF) just announced that it has parted ways with its Chief Advocacy Officer, John Fowler. The Company wishes to thank Mr. Fowler for his years of dedication and strong contribution to Supreme Cannabis and his passion for the cannabis plant. Mr. Fowler was one of the original founders of Supreme Cannabis’ flagship brand, 7ACRES, and is a strong believer in the cultivation of high-end cannabis. As a pioneer and passionate advocate for legalization, the Company knows Mr. Fowler will continue to be a strong contributor to our cannabis community. “We all wish John the best in his next endeavor and thank him for his commitment to the Company for the last four years. John recognized the value of high-quality cannabis at scale and was instrumental in the creation of 7ACRES,” said Navdeep Dhaliwal, CEO. “The Company and its strong management team is excited to continue its path to growth as a leader in differentiated cannabis brands and premium cultivation at scale, while exporting our team’s vast knowledge and experience globally.”

Flowr Corporation (TSX-V:FLWR)(OTCPK:FLWPF) announced that Ivan Latysh has joined the Company as Chief Technology Officer.  In this newly created position, Mr. Latysh will be responsible for developing and overseeing the execution of Flowr’s technology and data-driven strategies.  He will collaborate with all departments including, finance, operations, sales and marketing to support the Company’s objectives. Mr. Latysh was most recently, and since 2015, Vice President, Information Technology at MedReleaf Corporation, a cannabis producer focused on the medical market.  “The addition of Ivan to our executive leadership team will ensure our operations and commercialization initiatives are supported by the technology and data-driven strategies that are necessary to excel in today’s market,” commented Flowr’s Chief Executive Officer, Vinay Tolia.  “Enhancing our capabilities in this area are critical as we integrate our recent acquisition of operational footprints in Europe and Australia.” In addition, the Company has appointed Messrs. Laurence Levi and Francesco Tallarico to the roles of Chief Strategy Officer and Chief Legal Officer, respectively.  Mr. Levi joined the Company in January, 2019, as Executive Vice President, Head of Strategy, and Mr. Tallarico joined the Company effective October 1, 2018, as General Counsel and Corporate Secretary.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM was compensated thirty five hundred dollars for news coverage of current press releases issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

$LXRP Names New Senior Advisor

$CNPOF $RIV.V Ontario University to Study Cannabidiol as a Dog Cancer Treatment

November 5, 2019

Cannabidiol (CBD) is slowly but surely making a name for itself as the miracle drug of the decade, if not century. The controversial cannabis extract has powerful medicinal properties that make it effective against a variety of conditions, from chronic pain and high blood pressure to severe forms of childhood epilepsy. With funding from a Toronto animal health company, researchers in Ontario are looking to see if the compound is just as effective against cancer in dogs.

The three-year study is the first of its kind in Canada, and it will try to prove if cannabis can be used to treat canine cancer. In a press release on Tuesday, The University of Guelph’s Ontario Veterinary College (OVC) said the research would “help point the way to alternative pet therapies.” It will focus primarily on CBD’s ability to treat bladder cancer in canines, particularly on a common and hard to treat variant known as urothelial carcinoma.

These tumors are responsible for two percent of all cancers in all dog breeds, and they are especially challenging to remove in surgery for both humans and dogs. The Veterinary College’s Dean Jeff Wichtel said in a statement that “veterinarians and pet owners have been eager for information on the medical applications for cannabis. This groundbreaking work will help us learn about the role of cannabinoids in cancer and advance the field of medical research in Canada.”

With the data from the study, researchers will be able to kill two birds with one stone. A statement released by lead researcher Professor Sam Hocker said that apart from identifying alternative treatments for canine cancer, the new study could “ultimately help in designing potential therapeutic options for the more aggressive form of bladder cancer in humans.” Researchers will study how CBD interacts with the cancer cells, whether the compound kills the cells, and how it works when paired with radiation and chemotherapy treatment.

The three-year study will be funded by Grey Wolf Animal Health, a specialty animal health company that focuses on improving the life and well-being of pets in Canada. The company will also supply the OVC with CBD oil for use during the study. Ian Sandler, Grey Wolf CEO, said that the company is thrilled to be supporting the study at a Canadian veterinary school. “This research at the University of Guelph will meet a growing need for treatments in the exciting and emerging field of veterinary cannabinoid medicine.”

It is believed that CBD companies like Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) and LiveWire Ergogenics Inc. (OTC: LVVV) will look forward to the outcome of this research since it will increase the credibility of CBD as a therapeutic compound.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

$POAI New Hope in the Battle Against Ovarian Cancer